C.OliverHanemann,MD,PhDJaishriO.Blakeley,MDFabioP.Nunes,MD,MMScKentRobertson,MDAnatStemmer-Rachamimov,MDVictorMautner,MDAndreasKurtz,PhDMichaelFerguson,MDBrigitteC.Widemann,MDD.GarethEvans,MDRosalieFerner,MDStevenL.Carroll,MD,PhDBruceKorf,MD,PhDPierreWolkenstein,MDPamelaKnightScottR.Plotkin,MD,PhDFortheREiNSInternationalCollaborationCorrespondencetoDr.Hanemann:Oliver.Hanemann@plymouth.ac.ukSupplementaldataatNeurology.orgCurrentstatusandrecommendationsforbiomarkersandbiobankinginneurofibromatosisABSTRACTObjective:Clinicallyvalidatedbiomarkersforneurofibromatosis1(NF1),neurofibromatosis2(NF2),andschwannomatosis(SWN)havenotbeenidentifiedtodate.Thebiomarkerworkinggroup’sgoalsareto(1)definebiomarkerneedsinNF1,NF2,andSWN;(2)summarizeexistingdataonbiomarkersinNF1,NF2,andSWN;(3)outlinerecommendationsforsamplecollectionandbiomarkerdevelop-ment;and(4)standardizesamplecollectionandmethodologyprotocolswherepossibletopromotecomparisonbetweenstudiesbypublishingstandardoperatingprocedures(SOPs).Methods:ThebiomarkergroupreviewedpublisheddataonbiomarkersinNF1,NF2,andSWNandonbiobankingeffortsoutsidethesediseasesvialiteraturesearch,definedtheneedforbio-markersinNF,anddevelopedrecommendationsinaseriesofconsensusmeetings.Results:WedescribeexistingbiomarkersinNFandreportconsensusrecommendationsforSOPandaminimalclinicaldatasettoaccompanysamplesderivedfrompatientswithNF1,NF2,andSWNindecentralizedbiobanks.Conclusions:TheserecommendationsareintendedtoprovidecliniciansandresearcherswithacommonsetofguidelinestocollectandstorebiospecimensandforestablishmentofbiobanksforNF1,NF2,andSWN.Neurology®2016;87(Suppl1):S40–S48GLOSSARY5-S-CD55-S-cysteinyldopa;ADM5adrenomedullin;MIA5melanomainhibitoryactivity;MPNST5malignantperipheralnervesheathtumors;NF15neurofibromatosis1;NF25neurofibromatosis2;PNF5plexiformneurofibromas;REiNS5ResponseEvaluationinNeurofibromatosisandSchwannomatosis;sAXL5solublegrowthfactorreceptorAxl;SOP5standardoperatingprocedure;SWN5schwannomatosis.Theneurofibromatoses—neurofibromatosis1(NF1),neurofibromatosis2(NF2),andschwan-nomatosis(SWN)—aregeneticallydistinctneurocutaneoussyndromesthatsharemanyfeatures.All3conditionsdemonstratewidevariabilityindiseasemanifestations,andarecharacterizedbyprogressive,lifelong,andpotentiallylife-threateningcomplications.Standardtreatmentislimitedtosurgeryformosttumormanifestations.Giventheunmetneedfornonsurgicaltherapies,therehavebeen.20clinicaltrialsperformedbetween1993and2014forNF1andNF2withvaryingmeasuresofresponse.Fewstudieshavedocumentedevidenceofclinicalefficacyforinvestigationalagents.1Todate,nobiomarker-driventrialshavebeenperformedinNF.TheResponseEvaluationinNeurofibromatosisandSchwannomatosis(REiNS)InternationalCollaborationwascreatedin2011todefineanddevelopthemostinformative,reliable,andmean-ingfulendpointsforclinicaltrialsforNF.TheREiNSgroupiscomposedofseveralworkinggroups.2Thebiomarkerworkinggroup,whichincludesneurologists,oncologists,geneticists,FromPlymouthUniversity(C.O.H.),PeninsulaSchoolsofMedicineandDentistry,TheInstituteofTranslationalandStratifiedMedicine,Plymouth,UK;DepartmentofNeurology(J.O.B.),JohnsHopkinsUniversityMedicalSchool,Baltimore,MD;DepartmentofPediatrics(F.P.N.)andDepartmentofPediatrics,SchoolofMedicine(K.R.,M.F.),IndianaUniversity;TailoredTherapeutics(F.P.N.),EliLillyandCompany,Indianapolis,IN;DepartmentofPathology(A.S.-R.),Neuro-oncology(S.R.P.),MassachusettsGeneralHospital,Boston;NeurologischeKlinik(V.M.),UniklinikEppendorf,Hamburg;Berlin-BrandenburgCenterforRegenerativeTherapies(A.K.),CharitéUniversitätsmedizinBerlin,Germany;SeoulNationalUniversity(A.K.),CollegeofVeterinaryMedicineandResearchInstituteforVeterinaryScience,RepublicofKorea;NCI(B.C.W.),PediatricOncologyBranch,Bethesda,MD;GenomicMedicine(D.G.E.),UniversityofManchester,UK;NationalNeurofibromatosisService(R.F.),DepartmentofNeurology,Guy’sandSt.Thomas’NHSFoundationTrust,LondonUK;DepartmentofPathologyandLaboratoryMedicine(S.L.C.),MedicalUniversityofSouthCarolina,Charleston;andHeflinCenterforGenomicSciences(B.K.),UniversityofAlabamaatBirmingham;Dermatology(P.W.),GHUHenriMondor,Paris,France;Children’sTumorFoundation(P.K.),NewYork.REiNSInternationalCollaborationmembersarelistedontheNeurology®WebsiteatNeurology.org.GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle.S40©2016AmericanAcademyofNeurologyª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.pathologists,dermatologists,pediatricians,andbasicscientists,hasthegoalsto(1)definebio-markerneedsinNF1,NF2,andSWN;(2)summarizeexistingdataonbiomarkersinNF1,NF2,andSWN;(3)outlineinitialrecom-mendationsforsamplecollectionandbiomarkerdevelopment;and(4)harmonizesamplecollec-tionandprocessingprotocolswherepossibletoallowfordatacomparisonbetweenstudiesbypublishingstandardoperatingprocedures(SOPs).Thisarticlesummarizestheprogresstowardthesegoals.Thebiomarkergrouphasconcen-tratedonbiomarkersinblood,urine,andtissue.ImagingbiomarkersarediscussedseparatelybytheREiNSimagingworkinggroup.3METHODSThebiomarkergroupfirstperformedaliteraturesearch,andreviewedandsummarizedexistingdataonbiomarkersinNF1,NF2,andSWN.ThegroupthenmetduringaseriesofmeetingsincollaborationwiththeChildren’sTumorFoundation(1)toestablishSOPsforsamplecollectionofNFtissuespecimensthatfacilitatedatacomparisonbetweenstudiesand(2)todevelopaminimalclinicaldatasetthatwouldaccompanyeachsample.Theworkinggroupanticipatesthattheserecommendationswillbeupdatedperiodicallyasnewinformationonbiomarkersbe-comesavailable.DetailedassayprotocolswillbeavailableontheREiNSWebsite(www.reinscollaboration.org).RESULTSBiomarkersareusedforearlydetectionofdiseaseorindiseaseclassification(diagnosticbiomarkers),inpredictingresponseoradverseevents(predictivebio-markers),indefiningoptimaldrugdose(metabolic/phar-macodynamicbiomarkers),orinforecastingprogressionorrecurrence(outcomebiomarkers).4PreviousnaturalhistorystudiesinNF1andNF2haveclearlydemon-stratedahighdegreeofvariabilityindiseasephenotypeandtumorbehaviorintheseconditions.5Thisvariabilityintroducescomplexityintotheidentificationofvalidbio-markersforNFandschwannomatosis.Forexample,abiomarkercouldpotentiallycorrelatewiththepresenceofthegeneticsyndrome(e.g.,NF1,NF2,orschwanno-matosis),ofaspecifictumortype(e.g.,gastrointestinalstromaltumorinNF1),withanontumorphenotypeofNF(e.g.,painseverityinschwannomatosis),withcumu-lativediseaseburden(e.g.,wholebodytumorburden),withdiseaseprogression(e.g.,growthofplexiformneu-rofibromainNF1),orwithmalignanttransformation(e.g.,malignantperipheralnervesheathtumorfromplex-iformneurofibroma).Giventheoverlapinmanyofthesephenotypes,validatingthesebiomarkersforindividualdiseasemanifestationswillrequirecarefulphenotypingofpatients.DiagnosticbiomarkersinNF.Historically,NF1,NF2,andschwannomatosishavebeendiagnosedusingestablishedclinicalcriteria.Advancesinmoleculartechniquesoverthelast2decadeshaveledtotheavailabilityofgeneticdiagnosisfortheseconditions.6,7ThesensitivityofgeneticanalysisfordiagnosisofNFdependsonthefounderstatusandtheclinicalphenotype(segmentalvsgeneral-ized)butrangesfrom30%forsporadicschwannomatosisto.95%forNF1.WhenacausativegeneticalterationintheNF1,NF2,SMARCB1,orLZTR1genesisidenti-fied,itcanbeusedasdiagnosticbiomarkerforrelatedfamilymembers.Inclinicalpractice,thisinformationisusedbyreproductiveendocrinologistsforprenataldiagno-sisorpreimplantationgeneticdiagnosisandbygeneticcounselorsforpresymptomaticdiagnosisoffamilymem-bers.However,additionaldiagnosticbiomarkerswillundoubtedlybeusefultoidentifypatientswithspecificdiseasefeatures,suchasplexiformneurofibromasoropticgliomas.OutcomebiomarkersinNF.Similarly,thereisgreatvariabilityinclinicaloutcomesforpatientswithNF.Forexample,whileopticpathwaygliomaoccursinabout15%ofindividualswithNF1,onlyabout1/3ofthesetumorsaresymptomatic,andlesswillprogressandrequireactivetreatment.8Opticpathwaygliomaswillevenspontaneouslyregresswithouttreatment.ThisvariabilityinoutcomehighlightstheneedtodevelopoutcomebiomarkersforNFdiseasemanifes-tations.Outcomebiomarkersprovideevidenceaboutthepatient’sdiseaseoutcomeindependentofanyspecificintervention.Avalidatedoutcomebiomarkerwouldbevaluabletodeterminethelong-termriskfordermalneurofibromasandmalignantperipheralnervesheathtumorsinpatientswithNF1,forriskofcompletedeafnessinpatientswithNF2,andforriskofseverechronicpaininpatientswithschwannomatosis.PredictivebiomarkersinNF.Overthelastdecade,therehasbeenanexplosionofclinicaltrialsforNF-relatedtumorsandconditions.TheopportunitytostudynovelagentsinNFopensthepossibilityofdevelopingandincorporatingbiomarkerstudiesintoearlyclinicaltrials.Todate,clinicaltrialsrunthroughtheNeurofibromatosisClinicalTrialsConsortiumhaveincludedstudiesofpharmacodynamicbiomarkersandpredictivebiomarkers.AsdrugswithactivityagainstNFbecomeavailable,thesestudieswillprovidevaluableinformationaboutwhichpatientsarelikelytorequiretreatmentinthefutureandwhicharelikelytorespondtotherapy.ExistingdataonbiomarkersinNF1,NF2,andSWN.Duringdevelopment,biomarkerspassthroughaseriesofstages,includingearlyresearchanddevelopment(exploratorybiomarker),demonstrationandvalidation(probablebiomarker),characterizationandqualification(knownbiomarker),andsurrogacy(biomarkercansubsti-tuteforclinicalendpoint).Fortheneurofibromatoses,allNeurology87(Suppl1)August16,2016S41ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.biomarkerspublishedtodateareconsideredexploratory;nonehasbeenvalidatedtoachieveprobablebiomarkerstatus.Thusfar,allpublishedbiomarkerstudieshavebeenperformedinthesettingofNF1(table1);therearenopublisheddataonbiomarkersinNF2orschwan-nomatosis.Theseexploratorystudiesarealllimitedbyavarietyoftechnicalissuessuchaslimitedstatisticalpower,lackofanindependentvalidationset,andlackoflongitudinaldata.DiagnosticbiomarkersinNF1.(cid:129)Melanomainhibitoryactivity(MIA)—Inastudyof42patientswithNF1and22healthycontrols,9MIAserumlevelsweresignificantlyTable1Exploratorybiomarkerstudiespublishedforneurofibromatosis1(NF1)BiomarkerCorrelatewithNFpatients,nControls,nResultReferenceDiagnosticbiomarkersMIANF1status4222GreaterinNF1thaninunaffectedcontrols9TumorloadGreaterinNF1withPNFthaninNF1withoutPNFMPNSTGreaterinpatientswithNF1withhighertumorburdenNodifferencebetweenpatientswithNF1withorwithoutMPNSTMIA5-S-CDNF1status2514MIAgreaterinNF1thaninunaffectedcontrols10PNFstatusNodifferenceinMIAbetweenpatientswithNF1withorwithoutPNFAgeMIAlevelscorrelatewithage5-S-CDgreaterinNF1thaninunaffectedcontrols5-S-CDdoesnotcorrelatewithageADMMPNST3225HigherADMlevelsinNF1withMPNSTthaninNF1withPNF11NodifferencebetweenpatientswithNF1withorwithoutPNFHigherADMlevelsinpatientswithNF16PNFthanincontrolsIL-6,IFN-g,TNF-a,EGFRNF1status10441SerumconcentrationsofIL-6,IFN-g,andTNF-aweresignificantlyhigherinNF1thaninhealthycontrols14MPNSTstatusSerumconcentrationsofEGFRweresignificantlylowerinNF1thaninhealthycontrolsIGFBP-1,RANTESNF1status10441SerumconcentrationsofIGFBP-1andRANTESweresignificantlyhigherinpatientswithNF1withMPNSTthaninthosewithoutMPNST14MPNSTstatusSerumIGFBP-1correlatedwithinternaltumorloadInternaltumorloadFetalantigen1NF113177Statisticallysignificantdifferencebetweenmedianvalues12NotabletodistinguishbetweengroupssAXLNF1diagnosis,presenceofNF17246IncreasedinpatientswithNF1comparedtocontrols13IncreasedinpatientswithNF1withPNFcomparedtothosewithoutRASSF1AmethylationMPNST20MPNTSmethylated,12unmethylatedMPNSTwithRASSF1methylatedhadworseprognosisthanunmethylated,p50.01415miR-204MPNST12NF1,10NF11MPNSTDownregulationofmiR-204downregulatedinMPNST16PredictivebiomarkersFOXM1Survival38MPNSTHighFOXM1proteinexpressionwaspredictorofpoorsurvivalforpatientswithNF1withMPNST17CDK4Survival38MPNSTCDK4copynumbergainbyaCGHwaspredictorofpoorsurvivalforpatientswithNF1withMPNST17Survivin/TK1,TOP2ASurvivalwithMPNST64NF1withMPNSTStratifiesMPNSTintohighandlowrisk20Abbreviations:5-S-CD55-S-cysteinyldopa;aCGH5arraycomparativegenomichybridization;ADM5adrenomedullin;EGFR5epidermalgrowthfactorreceptor;IFN5interferon;IL5interleukin;MIA5melanomainhibitoryactivity;miR5microRNA;MPNST5malignantperipheralnervesheathtumors;PNF5plexiformneurofibromas;sAXL5solublegrowthfactorreceptorAxl;TNF5tumornecrosisfactor.S42Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.greaterinpatientswithNF1(15.2ng/mL)thanincontrols(4.5ng/mL),inpatientswithNF1withplexiformneurofibromas(PNF)thaninthosewithoutPNF,inpatientswithNF1withhighnumbersofcutaneousorsubcutaneousneurofibromasthaninthosewithoutsuchtu-mors,andinpatientswithNF1withgreaterinternaltumorloadthaninthosewithlowinter-naltumorload.Incontrast,serumlevelsofMIAwerenotsignificantlydifferentbetweenpatientswithNF1withandwithoutmalignantperipheralnervesheathtumors(MPNST).MIAasabio-markerforNF1wasalsoinvestigatedbyanothergroup.10Thisgroupaddedtheanal-ysisofthemetabolite5-S-cysteinyldopa(5-S-CD).TheyfoundconcordantresultswithhigherMIAlevelsin25patientswithNF1comparedwith14controls(13.1vs9.3ng/mL)butdidnotfindsignificantlydif-ferentlevelsbetweenpatientswithNF1withorwithoutPNF(15.1vs12.0ng/mL,respectively).Intheirstudy,serum5-S-CDlevelsweresignif-icantlyhigherinpatientswithNF1thanincon-trolsanddidnotcorrelatewithage.Hence,MIAdoesnotappeartobearobustbiomarkerfordistinguishingunaffectedcontrolsfrompatientswithNF1orbetweenpatientswithNF1withorwithoutMPNST.Furtherworkisneededtoexploretheutilityof5-S-CDtodistinguishbetweengroups.(cid:129)Adrenomedullin(ADM)—Inastudyof32patientswithNF1and25controlpatients,11serumADMlevelsweresignificantlygreaterinpatientswithNF1withMPNST(0.24ng/mL,n55)thaninpatientswithNF1withPNF(0.18ng/mL,n517);however,therewassignificantoverlapinADMlevelsbetweenthecohorts.ADMlevelswerealsosignificantlyhigherinpatientswithNF1withorwithoutMPNST(0.18ng/mL,n527)thanincontrols(0.07ng/mL,n525).Nosignif-icantdifferenceswerenotedbetweenpatientswithNF1withorwithoutPNF.AlthoughthedataforADMdataaremorepromisingthanthoseforMIA,thecurrentdatadonotindicatethatADMisareli-ablebiomarkerinNF1andfurtherstudiesarewarranted.(cid:129)Fetalantigen1—Inastudyof13adultpatientswithNF1and177adultcontrols,12themedianfetalantigen1levelsweresignificantlyhigherintheserumofpatientswithNF1(30.6ng/mL)thanincontrolpatients(24.9ng/mL),althoughtherewasconsiderableoverlapbetweenthegroups.12(cid:129)SolublegrowthfactorreceptorAxl(sAXL)—Inastudyof72patientswithNF1and46healthycontrols,serumlevelsofsAXLweresignificantlyincreasedinpatientswithNF1(23ng/mL)comparedwithcontrols(16ng/mL).PatientswithplexiformneurofibromashadsignificantlyhigherlevelsofsAXL(26ng/mL,n536)thanpatientswithNF1withoutplexiformneurofibromas(18ng/mL,n536)althoughtherewasstillsomeoverlapbetweengroups.13(cid:129)Systematicscreenofmultipleserumbio-markers14—Theauthorsevaluated104pa-tientswithNF1and41healthycontrolsandproposed4candidatebiomarkersthatweresta-tisticallysignificantlydifferentinpatientswithNF1vsunaffectedindividuals(interleukin-6,interferon-g,epidermalgrowthfactorreceptor,tumornecrosisfactor–a)and2biomarkercan-didatesthatwerestatisticallysignificantlydif-ferentinpatientswithNF1withandwithoutMPNST(insulin-likegrowthfactorbindingprotein1andRANTES).(cid:129)Danielsenetal.15analyzedthepromotermethyl-ationofRASSF1Ainprimarytumor.Theau-thorsreportedsignificantlydifferentsurvivaldatafor32patientswithmethylatedorunmethy-latedRASSF1Aat5years.(cid:129)MiRNAstudiesinNF1andnon-NF1MPNSTshavebeenperformedusingcelllinesandtissues.ThisstudyidentifiedthedownregulationofmiR-204asanoveldiagnosticbiomarkerandpotentialtherapeutictargetforpatientswithNF1withMPNSTs.16Alltheabove-mentionedstudieswereaimedatidentifyingdiagnosticbiomarkers.Predictiveandpharmacodynamicbiomarkers.(cid:129)Candidategenealterationsintumorspecimens—Usinghigh-resolutionarray-basedcomparativegenomichybridizationin38MPNSTs(23withNF1and15withoutNF1),theauthorsidenti-fiedcandidategenealterationsthatwerethenvalidatedattheDNA,RNA,andproteinlevels.17Candidategenesinregionsofcopynumbergainandassociated(predicted)withpoorsurvivalincludedSOX5,NOL1,MLF2,FOXM1,FKBP1,CDK4,TSPAN31,ERBB2,MYC,andTP53.Inmultivariateanalysis,FOXM1proteinexpressionandCDK4copynumbergainwerethemostsig-nificantindependentgenomicbiomarkersforpoorsurvivalinpatientswithMPNSTs.(cid:129)AurorakinaseA,whichisimportantinmitoticspindleassemblyandnonmitoticrelatedcelldif-ferentiation,isapotentialtherapeutictargetinMPNSTs.RecentstudiesinprimaryMPNSTshavedemonstratedthatpharmacologicaurorakinaseinhibitionresultsinMPNSTcellsNeurology87(Suppl1)August16,2016S43ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2RecommendedminimalclinicaldatasetDemographicsDate:SexmalefemaleBirthmonthyearDiagnosisofNF1,NF2,orschwannomatosisinfancychildhoodadolescenceadulthoodunknownInheritanceparentaffectedparentnotaffectedunknownMosaicismpatientismosaicpatientnotmosaicunknownGermlinemutationnottestedtested1unknowndetermined:(specify___)ClinicalstatusStatusalivedeceasedWHOperformancestatus01234PainnotaproblemoccasionaldisablingTreatmentdirectedattumornospecifictherapychemotherapysurgeryradiationtargetedtherapy(specify)clinicaltrial(specify)NF1‡6Café-au-laitmaculesabsentpresentunknownSkinfoldfrecklingabsentpresentunknownIrisLischnodulesabsentpresentunknownDermalneurofibromasabsentscattereddenseunknownSubcutaneousnodularneurofibromasabsentscattereddenseunknownDiffusedermalneurofibromasabsentscattereddenseunknownSpinalneurofibromasnotimagedabsent1–3levelsalllevels(cervical,thoracic,lumbar,sacral)unknownPlexiformneurofibromaspresentabsentbyMRIabsentclinically,butnoMRIunknownOpticgliomaunknownabsentpresent,asymptomaticpresent,symptomatic,nottreatedpresent,symptomatic,treatedHeartdefectunknownabsentpresent(specify)Vasculardiseaseunknownabsentpresent(specify)PubertyonsetprepubertalprecociousnormallateunknownStature,5thcentile5th–95thcentile.95thcentileunknownPeripheralneuropathyunknownabsentpresentAqueductalstenosisunknownabsentpresentLongbonedysplasiaunknownabsentpresentSphenoiddysplasiaunknownabsentpresentScoliosisunknownabsentpresentIntellectualdisabilityunknownabsentpresentContinuedS44Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2ContinuedNF1LearningdisabilityunknownabsentpresentAttentiondeficitdisorderunknownabsentpresentPheochromocytomaunknownabsentpresentGlomustumorunknownabsentpresentMPNSTunknownabsentpresentGlioma(notopticglioma)unknownabsentpresentGISTunknownabsentpresentLeukemiaunknownabsentpresentBreastcancerunknownabsentpresentOthertumorsunknownabsentpresent(specify_____)NF2VestibularschwannomaMRInotdoneabsentbyMRIunilateralbilateralunknownMeningiomaMRInotdoneabsentbyMRIsinglemultipleunknownGlioma/ependymomaMRInotdoneabsentbyMRIpresentunknownSpinalschwannomaMRInotdoneabsentbyMRIsinglemultipleunknownDermalschwannomaunknownabsentpresentNonvestibularcranialschwannomaMRInotdoneabsentbyMRIpresent(specify)unknownLenticularopacityunknownabsentpresentSchwannomatosisSchwannomas(nonvestibular)onlybyimagingevidence1pathologicallyconfirmed2ormore,atleast1pathologicallyconfirmedunknownNumberofschwannomassinglescattereddenseunknownVestibularschwannomasnotimagedabsentbyimagingunilateralbilateralunknownMeningiomasnotimagedabsentbyimagingsinglemultipleunknownOtherschwannomatosis-relatedtumors(pleasespecify)notinvestigatedabsentpresentunknownAbbreviations:GIST5gastrointestinalstromaltumors;MPNST5malignantperipheralnervesheathtumors;NF15neurofibromatosis1;NF25neurofibromatosis2.Neurology87(Suppl1)August16,2016S45ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.exitingthecellcyclewithcessationofgrowth.18ThecopynumberandexpressionofthegeneproductHMMRwasfoundtobeafunctionalmarkerofresponsivenesstoaurorakinaseinhibition.Avarietyoflesswell-definedandreproducibleprognosticatorsaresummarizedinareviewbyFaridetal.19(cid:129)Recently,geneexpressionanalysisof30MPNSTsandsubsequentimmunohistochemicalstainingof64MPNSTsrevealedacompositesetofsur-vivin(BIRC5),thymidinekinase1(TK1),andtopoisomerase2-a(TOP2A)immunohistochem-icalstaining,whichstratifiesMPNSTintohighandlowrisk20independentofage,sex,tumorsize,grade,NF1status,andsurgicalremission.(cid:129)Blakeleyetal.21havedetectedlowerbloodcircu-latinglevelsofhepatocytegrowthfactorinpatientswithNF2whorespondedtobevacizumab.ThisisthefirstevidencethatabloodbiomarkercouldbeusedpredictivelytostratifypatientswithNF2(n513)withthehighestlikelihoodoftreatmentbenefit.RECOMMENDATIONSFORSAMPLECOLLECTIONANDMETHODOLOGYTheREiNSbiomarkergroupdiscussedpotentialbarrierstobiomarkerresearchforNF.ThesebarriersincludethelowprevalenceofNF1,NF2,andschwannomatosis,whichmakescoordinatedstudiestechnicallydifficultandexpensive;theextremevariabilityoftheseconditionsrequiresexpertclinicalresearcherstoaccuratelyphenotypepatients.Basedonthisdiscussion,thegroupendorsedthefollowinggoalstoadvancethestudyofbiomarkerswithintheNFcommunity:1.Buildaprospectivebiorepositoryofcuratedsam-ples.Theaimwouldbetocollectlongitudinalsamplesfromeachpatienttofacilitatethedevel-opmentofearlydetectionandprognosticmarkers.2.Standardizetissuecollectionatparticipatinginstitu-tions.TheaimwouldbetocollectalltissuesusinganidenticalprotocolthatmeetsstandardssetforthbytheAmericanAssociationforCancerResearch–FoodandDrugAdministration–NationalCancerInstituteCan-cerBiomarkerCollaborative4andwouldbelinkedviaashared,anonymizedregistry(onaWebsite).Par-ticipatingsiteswouldsharecommonconsent,SOPs,qualitycontrol(seesupplementaldataontheNeurology®WebsiteatNeurology.org),minimalclin-icaldataset,anddatabase.3.Annotatesampleswithanagreedminimalclinicaldataset.Thegoalistolinkanonymouslythepheno-typicdatatodeidentifiedsamplesinthebioreposi-tory.AproposedminimalclinicaldatasetdevelopedataconsensusmeetinginOctober2014isshownintable2.Thegroupanticipatesthatmodificationsofthisdatasetmayberequiredinthefuturetooptimizetheutilityofbiomarkerresearch.4.Incorporatethedecentralizedbiorepositoryintoex-istingbiorepositoriesthatareusedfordiagnosticpurposes.Thebiomaterialcouldthusbeusedforbothdiagnosisandresearchandisnotnecessarilyrestrictedtoanupfrontdefinitionoftheamountofsurplustissue.Patientcaretakespreferencewhenallocatingtheamountofsamplesusedforbio-markerinvestigations.5.Provideopenaccesstodepositedbiomarkerstofacilitateresearch.Theaimwouldbetohavesam-plesanddataopentoallqualifiedresearcherswithapprovalofaninstitutionalreviewboard.Abiorepo-sitorycouncilwouldgoverndatabaserequests.6.AnoperationalandanexecutivecommitteewillgovernrequestsandauditimplementationofSOPsandqualitycontrolmeasures.7.Incorporatebiomarkercollectionintoclinicalstudies.Whenfeasible,samplecollectionshouldbeincorpo-ratedintoprospectiveclinicaltrialsandnaturalhis-torystudiestohelpdeveloppharmacodynamicandpredictivebiomarkers.8.Incorporatebiomarkercollectionintoroutineclin-icalvisits.Patientsreceivingroutinecareshouldbeinvitedtoparticipateinprospectivesamplecollec-tionduringroutineclinicvisits.RECOMMENDATIONSFORBIOMARKERSBASEDONEXISTINGDATA1.Validateindividualbiomarkersaswellascocktails/signaturesofbiomarkers.2.ForongoingandplannedNFtrials,studiesofdrugmetabolism/pharmacodynamicbiomarkersshouldbedrug-specific.3.FormalignanttumorssuchasMPNST,exploreandvalidatecDNA,cRNA,andcirculatingtumorcellsasbiomarkers.4.Validateuseofextracellularvesicles(exosomes)basedonencouragingpreliminarydataasbiomarkersofcancer.225.Usingcandidateapproach,focusontheclinicallyrelevantquestions,i.e.,totaltumorload,presenceofplexiformneurofibroma,evidenceofmalignanttransformation,andtakingintoaccountthestatisti-calsignificanceinpublishedstudies.Werecommendvalidatingthefollowingbiomarkercandidatesinpa-tientswithNF1:BIRC5/TK1/TOP2Aimmunohis-tochemistry,ADM,interferon-g,IGFBP-1,andsAXL.6.Complementcandidatebiomarkerapproachwithsys-tematicunbiasedapproach.Encouragewell-poweredstudiesusingsystematicunbiasedapproaches,includ-inggenomics(DNA,RNA,miRNAnext-generationsequencing),metabolomics,andproteomics;thatis,furtherscreeningwithmetabolomics,proteomics,expressionarrays,andmiRNA.S46Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.AUTHORCONTRIBUTIONSC.O.Hanemann:draftingthemanuscript,studyconcept,interpreta-tionofdata,developmentofrecommendationsandSOPs.JaishriBla-keley:studyconcept,reviewofmanuscript,interpretationofdata.FabioNunes:studyconcept,reviewofthemanuscript,developmentofrecommendations,developmentofSOPs.KentRobertson:studyconcept,reviewofmanuscript,developmentofSOPs.AnatStemmer-Rachamimov:studyconcept,reviewofmanuscript,develop-mentofSOPs.VictorMautner:studyconcept,reviewofmanuscript.AndreasKurtz:studyconcept,reviewofmanuscript,developmentofSOPs.MichaelFerguson:studyconcept,reviewofmanuscript,devel-opmentofSOPs.BrigitteC.Widemann:studyconcept,reviewofmanuscript.GarethEvans:studyconcept,reviewofmanuscript.Rosa-lieFerner:reviewofmanuscript,interpretationofdata.StevenL.Car-roll:draftingofmanuscript,developmentofautopsy,surgicalpathology,andbloodbiobankingprotocols.BruceKorf:interpretationofdata,reviewingmanuscript,draftingminimalclinicaldataset.PierreWolkenstein:reviewofmanuscript.PamKnight:studyconcept,reviewofmanuscript.ScottPlotkin:studyconcept,draftingofmanuscript,reviewofmanuscript.ACKNOWLEDGMENTTheauthorsthankChildren’sTumorFoundation(CTF)forsupportandXandraO.Breakefield,MassachusettsGeneralHospital,foradvisingonthemanuscript.STUDYFUNDINGNotargetedfundingreported.DISCLOSUREO.HanemannreceivessupportfromDr.HadwenTrustandBrainTumourResearch.J.BlakeleyhasreceivedresearchsupportfromGlaxoS-mithKline,Sanofi-Aventis,andLilyPharmaceuticals.ShehasconsultedforAbbvie.F.NunesreceivessupportfromEliLillyandCompany.K.RobertsonreceivesresearchsupportfromNovartis,NIH,DepartmentofDefense,andLeukemiaLymphomaSocietyTranslationalResearchPro-gram,andservesonamedicaladvisoryboardforGeneralBioTechnology—CookBiomedical.A.Stemmer-RachamimovreceivessupportfromChild-ren’sTumorFoundation,DanaFarberCancerInstitute,andNIH,andservesontheeditorialboardofJournalofClinicalPathology.V.Mautnerreportsnodisclosuresrelevanttothemanuscript.A.KurtzreceivessupportfromSeoulNationalUniversity,CollegeofVeterinaryMedicine,Novartis,andNolitolib,andservesontheeditorialboardofInternationalJournalofStemCells.M.FergusonservesasanassistantprofessorwithIndianaUniversity.B.WidemannreceivesresearchsupportthroughNCICCRIntramuralResearchProgram.G.EvansreceivedsupportfromAstraZenecaandhasservedontheboardofFamilialCancerJournal.R.FernerreceivesfundsfromtheChildren’sTumorFoundation,EuropeanNeurofibromatosisAssociation,andSpringerPublishingGroup.S.CarrolreceivedfundingfromtheDepartmentofDefense,NIH/NationalCancerInstitute,NIH/NINDS,andChildren’sTumorFoundation.HeservesontheeditorialboardsofJournalofNeuropa-thologyandExperimentalNeurology,Neuro-Oncology,TheAmericanJournalofPathology,andBrainResearchBulletin.B.KorfreceivesfundingfromNIH,DepartmentofDefense,Children’sTumorFoundation,TuberousSclerosisAlliance,andMarchofDimes.HeservesontheboardofNovartis,Accolade,andChildren’sTumorFoundationMedicalAdvisoryCommittee,andadvisesfortheNeurofibromatosisTherapeuticAccelerationProject.HehasservedaseditorforCurrentProtocolsinHumanGeneticsandAnnualReviewsofGeneticsandGenomics.HehasreceivedfundingfromtheAmericanCollegeofMedicalGeneticsandGenomics,AmericanAcademyofPediatrics,CambridgeHealth-TechInstitute,Illumina,andSequenome.HehasreceivedpublishingroyaltiesfromWileyBlackwellandElsevier.P.WolkenstreinservesontheadvisoryboardofAbbvieandPierreFabreDermatologieandconsultsforLaboratoired’UriageandLaboratoireExpansciences.HereceivesresearchsupportfromNovartisandtheFrenchGovernment(PHRC2010).P.Knightreportsnodisclosuresrelevanttothemanuscript.S.PlotkinreceivesresearchsupportfromChildren’sTumorFoundation,NIH,andtheDepartmentofDefenseNeu-rofibromatosisClinicalTrialsConsortium.GotoNeurology.orgforfulldisclosures.ReceivedNovember17,2015.AcceptedinfinalformMarch30,2016.REFERENCES1.PlotkinSR,Stemmer-RachamimovAO,BarkerFG,etal.Hearingimprovementafterbevacizumabinpatientswithneurofibromatosistype2.NEnglJMed2009;361:358–367.2.PlotkinSR,BlakeleyJO,DombiE,etal.Achievingcon-sensusforclinicaltrials:theREiNSInternationalCollab-oration.Neurology2013;81:S1–S5.3.DombiE,Ardern-HolmesSL,Babovic-VuksanovicD,etal.Recommendationsforimagingtumorresponseinneurofibromatosisclinicaltrials.Neurology2013;81:S33–S40.4.KhleifSN,DoroshowJH,HaitWN;AACR-FDA-NCICancerBiomarkersCollaborative.AACR-FDA-NCICancerBiomarkersCollaborativeconsensusreport:advancingtheuseofbiomarkersincancerdrugdevelopment.ClinCancerRes2010;16:3299–3318.5.FernerRE.Neurofibromatosis1andneurofibromatosis2:atwentyfirstcenturyperspective.LancetNeurol2007;6:340–351.6.LloydSK,EvansDG.Neurofibromatosistype2(NF2):diagnosisandmanagement.HandbClinNeurol2013;115:957–967.7.FernerRE,HusonSM,ThomasN,etal.Guidelinesforthediagnosisandmanagementofindividualswithneuro-fibromatosis1.JMedGenet2007;44:81–88.8.ListernickR,FernerRE,LiuGT,GutmannDH.Opticpathwaygliomasinneurofibromatosis-1:controversiesandrecommendations.AnnNeurol2007;61:189–198.9.KolanczykM,MautnerV,KosslerN,etal.MIAisapoten-tialbiomarkerfortumourloadinneurofibromatosistype1.BMCMed2011;9:82.10.YoshidaY,FurumuraM,TahiraM,HorieT,YamamotoO.Serumbiomarkerinneurofibromatosistype1.JDermatolSci2012;67:155–158.11.HummelTR,JessenWJ,MillerSJ,etal.Geneexpressionanalysisidentifiespotentialbiomarkersofneurofibromatosistype1includingadrenomedullin.ClinCancerRes2010;16:5048–5057.12.JensenCH,SchroderHD,TeisnerB,LaursenI,BrandrupF,RasmussenHB.Fetalantigen1,amemberoftheepidermalgrowthfactorsuperfamily,inneurofibro-masandserumfrompatientswithneurofibromatosistype1.BrJDermatol1999;140:1054–1059.13.JohanssonG,PengPC,HuangPY,etal.SolubleAXL:apossiblecirculatingbiomarkerforneurofibromatosistype1relatedtumorburden.PLoSOne2014;9:e115916.14.ParkSJ,SawitzkiB,KluweL,MautnerVF,HoltkampN,KurtzA.Serumbiomarkersforneurofibromatosistype1andearlydetectionofmalignantperipheralnerve-sheathtumors.BMCMed2013;11:109.15.DanielsenSA,LindGE,KolbergM,etal.MethylatedRASSF1Ainmalignantperipheralnervesheathtumorsidentifiesneurofibromatosistype1patientswithinferiorprognosis.NeuroOncol2015;17:63–69.16.GongM,MaJ,LiM,ZhouM,HockJM,YuX.MicroRNA-204criticallyregulatescarcinogenesisinmalignantperipheralnervesheathtumors.NeuroOn-col2012;14:1007–1017.17.YuJ,DeshmukhH,PaytonJE,etal.Array-basedcomparativegenomichybridizationidentifiesCDK4andFOXM1alterationsasindependentpredictorsofsurvivalinmalignantperipheralnervesheathtumor.ClinCancerRes2011;17:1924–1934.Neurology87(Suppl1)August16,2016S47ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.18.MohanP,CastellsagueJ,JiangJ,etal.Genomicimbal-anceofHMMR/RHAMMregulatesthesensitivityandresponseofmalignantperipheralnervesheathtumourcellstoaurorakinaseinhibition.Oncotarget2013;4:80–93.19.FaridM,DemiccoEG,GarciaR,etal.Malignantperipheralnervesheathtumors.Oncologist2014;19:193–201.20.KolbergM,HolandM,LindGE,etal.ProteinexpressionofBIRC5,TK1,andTOP2Ainmalignantperipheralnervesheathtumours:aprognostictestaftersurgicalresec-tion.MolOncol2015;9:1129–1139.21.BlakeleyJO,YeX,DudaDG,etal.Efficacyandbiomarkerstudyofbevacizumabforhearinglossresultingfromneu-rofibromatosistype2-associatedvestibularschwannomas.JClinOncol2016;34:1669–1675.22.KrosJM,MustafaDM,DekkerLJ,SillevisSmittPA,LuiderTM,ZhengPP.Circulatinggliomabiomarkers.NeuroOncol2015;17:343–360.S48Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.DOI 10.1212/WNL.00000000000029322016;87;S40-S48 Neurology(cid:160)C. Oliver Hanemann, Jaishri O. Blakeley, Fabio P. Nunes, et al. neurofibromatosisCurrent status and recommendations for biomarkers and biobanking inThis information is current as of August 15, 2016ServicesUpdated Information & http://www.neurology.org/content/87/7_Supplement_1/S40.full.htmlincluding high resolution figures, can be found at:Supplementary Material 002932.DC2http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000 002932.DC1http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000Supplementary material can be found at: References ref-list-1http://www.neurology.org/content/87/7_Supplement_1/S40.full.html##This article cites 22 articles, 9 of which you can access for free at: Subspecialty Collections http://www.neurology.org//cgi/collection/neurofibromatosisNeurofibromatosisfollowing collection(s): This article, along with others on similar topics, appears in the(cid:160) Permissions & Licensing http://www.neurology.org/misc/about.xhtml#permissionsits entirety can be found online at:Information about reproducing this article in parts (figures,tables) or in(cid:160) Reprints http://www.neurology.org/misc/addir.xhtml#reprintsusInformation about ordering reprints can be found online:rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All ® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology(cid:160)